What is the efficacy of risperidone in reducing self‑injurious behaviors and treating obsessive‑compulsive disorder?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 27, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Risperidone for Self-Injurious Behaviors and OCD

Risperidone is FDA-approved and effective for self-injurious behaviors in autistic disorder but is NOT a first-line treatment for OCD—it should only be used as augmentation to SSRIs in treatment-resistant OCD cases.

Self-Injurious Behaviors

FDA-Approved Indication

Risperidone is specifically FDA-approved for treating irritability associated with autistic disorder in children and adolescents (ages 5-17 years), which includes aggression toward others, deliberate self-injuriousness, temper tantrums, and quickly changing moods 1.

Evidence for Efficacy

  • In autistic disorder: Two 8-week placebo-controlled trials demonstrated significant improvement in self-injurious behaviors, with mean doses of 1.4-1.9 mg/day (0.05-0.06 mg/kg/day) 1
  • In intellectual disabilities: A 2023 meta-analysis showed a small effect size (SMD -0.238) for self-injury reduction post-intervention, with antipsychotics (including risperidone) demonstrating larger effects than other medications 2
  • Real-world evidence: Case series in adults with moderate to profound mental retardation showed significant reduction in aggression and self-injurious behavior, though sedation and restlessness were common side effects 3

Dosing Approach

Start at 0.25 mg/day (weight <20 kg) or 0.5 mg/day (weight ≥20 kg), titrating to clinical response. Typical effective doses range from 0.5-3.5 mg/day based on weight and response 1.

Obsessive-Compulsive Disorder

NOT First-Line Treatment

SSRIs are the first-line pharmacological treatment for OCD, not risperidone 4. CBT with exposure and response prevention (ERP) and SSRIs have superior evidence, with number needed to treat of 3 for CBT and 5 for SSRIs 4.

Role as Augmentation Only

Risperidone should be considered only after SSRI failure (inadequate response after 8-12 weeks at maximum tolerated doses) 4.

Evidence for Augmentation:

  • Mixed efficacy: One double-blind RCT showed 40% response rate with risperidone augmentation versus 0% with placebo in treatment-resistant OCD 5
  • Real-world data: In a large Indian OCD clinic database (n=92), only 24% achieved ≥25% reduction in Yale-Brown Obsessive-Compulsive Scale scores, and only 25% continued risperidone long-term due to ineffectiveness or intolerability 6
  • Comparative effectiveness: Risperidone may be more effective than aripiprazole for augmentation (72% vs 50% response rate), particularly for obsessions 7
  • Important caveat: One trial found CBT augmentation superior to risperidone augmentation of SSRIs 4

When to Consider Risperidone in OCD:

  1. After failure of at least two adequate SSRI trials (12 weeks each at maximum tolerated doses)
  2. When CBT is unavailable or not tolerated
  3. Particularly if comorbid tics or Tourette syndrome present 8
  4. Better insight at baseline predicts better response 5

Dosing for OCD Augmentation:

Start 0.5 mg/day, titrate to 0.5-3.0 mg/day based on response and tolerability 5. Typical effective dose is 3 mg/day 7.

Critical Safety Considerations

Metabolic and Movement Disorders

  • Weight gain: Mean gain of 2 kg in 3-8 weeks in pediatric trials; 5.5 kg at 24 weeks and 8 kg at 48 weeks in longer-term studies 1
  • Tardive dyskinesia: 0.1% incidence in pediatric trials, though reversible upon discontinuation 1
  • Somnolence: Most common adverse effect, particularly in first two weeks, with median duration of 16 days 1

Monitoring Requirements

  • Weight and metabolic parameters (glucose, lipids) at baseline and regularly during treatment
  • Movement disorder assessment at each visit
  • Risk-benefit reassessment ongoing, particularly given modest effect sizes in OCD

Clinical Algorithm

For Self-Injurious Behaviors (in autism/intellectual disability):

  1. Confirm diagnosis and rule out medical causes of behavior
  2. Start risperidone 0.25-0.5 mg/day based on weight
  3. Titrate every 5-7 days to clinical response (target 0.05-0.06 mg/kg/day)
  4. Monitor weight, sedation, and movement disorders closely

For OCD:

  1. First-line: SSRI monotherapy (12 weeks at maximum tolerated dose) OR CBT with ERP
  2. Second-line: Switch to different SSRI or add CBT if not already tried
  3. Third-line: Consider risperidone augmentation 0.5-3 mg/day ONLY if:
    • Failed ≥2 adequate SSRI trials
    • CBT unavailable/not tolerated
    • Patient has good insight (predicts better response)
  4. Reassess after 8 weeks; discontinue if <25% symptom reduction
  5. Monitor metabolic parameters and movement disorders throughout treatment

The evidence clearly supports risperidone for self-injurious behaviors in autism but relegates it to a third-line augmentation strategy in OCD with modest efficacy and significant side effect burden 2, 4, 8.

Related Questions

Can risperidone (Risperdal) be used to treat obsessive‑compulsive disorder, and what is the recommended dosing regimen?
What is the recommended risperidone dose for augmentation of obsessive‑compulsive disorder when added to an SSRI?
What are the optimal OCD medications for a bipolar patient currently taking lurasidone (Latuda), propranolol, and buspirone (Buspar) who has intrusive thoughts and irritability?
What are the best medication options for treating obsessive‑compulsive disorder in a patient who is currently taking mirtazapine (Remeron), trazodone, aripiprazole (Abilify), and hydroxyzine?
What is the optimal treatment plan for an 18‑year‑old patient with bipolar disorder and obsessive‑compulsive disorder who is currently on fluoxetine (Prozac) 20 mg, aripiprazole (Abilify) 10 mg, buspirone (Buspar) 10 mg twice daily, and trazodone 50 mg as needed for sleep, but continues to experience intrusive thoughts?
Which element of a system of care is represented by properly functioning resuscitation equipment?
What is the best food to eat after a large intravenous iron infusion in a female patient who underwent Roux-en-Y gastric bypass five years ago?
Is ambroxol indicated for the treatment of acute viral rhinopharyngitis?
How should an intravenous sodium bicarbonate drip be administered, including dosing and monitoring, for a patient with severe metabolic acidosis?
Does a patient with COVID-19 need DuoNeb (albuterol and ipratropium bromide) therapy?
What is a pessary device, its indications, insertion technique, follow-up care, and potential complications?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.